Loading...

Mitsuyasu, Ronald T

Title(s)Professor-in-Residence, Medicine
Phone310-825-3807
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
    NIH/NCI R21CA177310Aug 1, 2013 - Jul 31, 2015
    Role: Principal Investigator
    South American Program in HIV Prevention Research (SAPHIR)
    NIH/NIMH R25MH087222Aug 1, 2011 - May 31, 2021
    Role: Co-Principal Investigator
    AIDS Malignancy Clinical Trials Consortium (AMC)
    NIH/NCI U01CA121947Aug 29, 2006 - Jul 31, 2010
    Role: Principal Investigator
    AIDS Malignancy Consortium (AMC)
    NIH/NCI UM1CA121947Mar 1, 2006 - Aug 31, 2020
    Role: Principal Investigator
    AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM
    NIH/NCI U01CA070080Aug 1, 1999 - Mar 31, 2007
    Role: Principal Investigator
    AIDS INSTITUTIONAL TRAINING GRANT
    NIH/NIAID T32AI007388Aug 1, 1990 - Jun 30, 2001
    Role: Co-Principal Investigator
    AIDS CLINICAL TRIALS UNIT
    NIH/NIAID U01AI027660Jun 30, 1986 - Jun 30, 1991
    Role: Co-Principal Investigator
    PHYSICIAN-INVESTIGATOR DEVELOPMENT AWARD PROGRAM
    NIH/NCI K08CA000932Jun 1, 1984 - Apr 30, 1987
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Goldstone SE, Lensing SY, Stier EA, Darragh T, Lee JY, van Zante A, Jay N, Berry-Lawhorn JM, Cranston RD, Mitsuyasu R, Aboulafia D, Palefsky JM, Wilkin T. A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium Trial. Clin Infect Dis. 2019 03 19; 68(7):1204-1212. PMID: 30060087.
      View in: PubMed
    2. Rockstroh JK, Asmuth D, Pantaleo G, Clotet B, Podzamczer D, van Lunzen J, Arastéh K, Mitsuyasu R, Peters B, Silvia N, Jolliffe D, Ökvist M, Krogsgaard K, Sommerfelt MA. Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. PLoS One. 2019; 14(1):e0210965. PMID: 30699178.
      View in: PubMed
    3. Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, Ramos JC, Sparano J, Ambinder RF, Lee J, Cesarman E, Yahyaei S, Mitsuyasu R, Wachsman W. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018 12 26; 2(24):3618-3626. PMID: 30573564.
      View in: PubMed
    4. Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963. PMID: 30085241.
      View in: PubMed
    5. Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085. PMID: 30024859.
      View in: PubMed
    6. Polizzotto MN, Mitsuyasu RT. Clinical and scientific challenges in HIV-associated malignancies. Curr Opin HIV AIDS. 2017 01; 12(1):1-5. PMID: 27763914.
      View in: PubMed
    7. Sparano JA, Lee JY, Palefsky J, Henry DH, Wachsman W, Rajdev L, Aboulafia D, Ratner L, Fitzgerald TJ, Kachnic L, Mitsuyasu R. Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol. 2017 Mar; 35(7):727-733. PMID: 27937092.
      View in: PubMed
    8. Lee JY, Dhakal I, Casper C, Noy A, Palefsky JM, Haigentz M, Krown SE, Ambinder RF, Mitsuyasu RT. Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. J Cancer Epidemiol. 2016; 2016:2138259. PMID: 27882054.
      View in: PubMed
    9. Godbole SV, Nandy K, Gauniyal M, Nalawade P, Sane S, Koyande S, Toyama J, Hegde A, Virgo P, Bhatia K, Paranjape RS, Risbud AR, Mbulaiteye SM, Mitsuyasu RT. HIV and cancer registry linkage identifies a substantial burden of cancers in persons with HIV in India. Medicine (Baltimore). 2016 Sep; 95(37):e4850. PMID: 27631245.
      View in: PubMed
    10. Noy A, Lensing SY, Moore PC, Gupta N, Aboulafia D, Ambinder R, Baiocchi R, Dezube BJ, Henry D, Kaplan L, Levine AM, Mitsuyasu R, Ratner L, Reid E, Remick S, Sparano J, Tzachanis D, Wachsman W, Chadburn A. Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. Leuk Lymphoma. 2016 07; 57(7):1731-4. PMID: 26674561.
      View in: PubMed
    11. Epeldegui M, Lee JY, Martínez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martínez-Maza O. Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res. 2016 Jan 15; 22(2):328-36. PMID: 26384320.
      View in: PubMed
    12. Mitsuyasu RT. Non-AIDS-defining cancers. Top Antivir Med. 2014 Jun-Jul; 22(3):660-5. PMID: 25101532.
      View in: PubMed
    13. Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW. Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. PLoS One. 2014; 9(3):e92118. PMID: 24638072.
      View in: PubMed
    14. Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):291-300. PMID: 24525316.
      View in: PubMed
    15. Rudek MA, Moore PC, Mitsuyasu RT, Dezube BJ, Aboulafia D, Gerecitano J, Sullivan R, Cianfrocca ME, Henry DH, Ratner L, Haigentz M, Dowlati A, Little RF, Ivy SP, Deeken JF. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer. 2014 Apr 15; 120(8):1194-202. PMID: 24474568.
      View in: PubMed
    16. Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ, Zaia JA, Mellors JW. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr. 2013 Aug 01; 63(4):438-41. PMID: 23493152.
      View in: PubMed
    17. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG, Deeks SG, Martin JN, Maurer TA. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS. 2013 Jul 17; 27(11):1735-42. PMID: 23435301.
      View in: PubMed
    18. Borges ÁH, Silverberg MJ, Wentworth D, Grulich AE, Fätkenheuer G, Mitsuyasu R, Tambussi G, Sabin CA, Neaton JD, Lundgren JD. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013 Jun 01; 27(9):1433-41. PMID: 23945504.
      View in: PubMed
    19. Mitsuyasu R. Curing HIV: lessons from cancer therapy. Curr Opin HIV AIDS. 2013 May; 8(3):224-9. PMID: 23454863.
      View in: PubMed
    20. Dong Q, Oh JE, Yi JK, Kim RH, Shin KH, Mitsuyasu R, Park NH, Kang MK. Efavirenz induces autophagy and aberrant differentiation in normal human keratinocytes. Int J Mol Med. 2013 Jun; 31(6):1305-12. PMID: 23563240.
      View in: PubMed
    21. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry MJ, Jay N, Aboulafia DM, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM. High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. HIV Clin Trials. 2013 Mar-Apr; 14(2):75-9. PMID: 23611828.
      View in: PubMed
    22. Gabrielian A, MacCumber MM, Kukuyev A, Mitsuyasu R, Holland GN, Sarraf D. Didanosine-associated retinal toxicity in adults infected with human immunodeficiency virus. JAMA Ophthalmol. 2013 Feb; 131(2):255-9. PMID: 23411900.
      View in: PubMed
    23. Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 01; 31(1):58-64. PMID: 23169503.
      View in: PubMed
    24. Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, Sharma SK, Samantaray JC, Ranjan S, Ekka M, Sreenivas V, Mitsuyasu RT. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis. 2012 Jul 31; 12:168. PMID: 22846195.
      View in: PubMed
    25. Sinha S, Dhooria S, Kumar S, Shah N, Velpandian T, Ravi A, Kumar N, Ahmad H, Bhargwa A, Chug K, Bumma N, Chandrashekhar R, Ekka M, Sreenivas V, Sharma SK, Samantaray J, Mitsuyasu R. The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment. AIDS Res Ther. 2011 Nov 02; 8(1):41. PMID: 22047185.
      View in: PubMed
    26. Reddy D, Mitsuyasu R. HIV-associated multicentric Castleman disease. Curr Opin Oncol. 2011 Sep; 23(5):475-81. PMID: 21760504.
      View in: PubMed
    27. Mitsuyasu RT, Zack JA, Macpherson JL, Symonds GP. Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt. Stem Cells Int. 2011; 2011:393698. PMID: 21716651.
      View in: PubMed
    28. Hoffman RM, Jamieson BD, Bosch RJ, Currier J, Kitchen CM, Schmid I, Zhu Y, Bennett K, Mitsuyasu R. Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals. J Clin Immunol. 2011 Oct; 31(5):873-81. PMID: 21643890.
      View in: PubMed
    29. Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011; 80(1-2):42-9. PMID: 21606663.
      View in: PubMed
    30. Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment. J Interferon Cytokine Res. 2011 Jun; 31(6):481-3. PMID: 21291323.
      View in: PubMed
    31. King WD, Wyatt GE, Liu H, Williams JK, DiNardo AD, Mitsuyasu RT. Pilot assessment of HIV gene therapy-hematopoietic stem cell clinical trial acceptability among minority patients and their advisors. J Natl Med Assoc. 2010 Dec; 102(12):1123-8. PMID: 21287892.
      View in: PubMed
    32. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R. Cancer biomarkers in HIV patients. Curr Opin HIV AIDS. 2010 Nov; 5(6):531-7. PMID: 20978397.
      View in: PubMed
    33. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010 Oct 15; 202(8):1246-53. PMID: 20812850.
      View in: PubMed
    34. Stapleton JT, Chaloner K, Zhang J, Klinzman D, Souza IE, Xiang J, Landay A, Fahey J, Pollard R, Mitsuyasu R. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS. 2009 Mar 13; 23(5):605-10. PMID: 19194270.
      View in: PubMed
    35. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med. 2009 Mar; 15(3):285-92. PMID: 19219022.
      View in: PubMed
    36. Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, Kitchen CM, Yang OO, Harley CB, Effros RB. Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol. 2008 Nov 15; 181(10):7400-6. PMID: 18981163.
      View in: PubMed
    37. Mitsuyasu RT. Non--AIDS-defining malignancies in HIV. Top HIV Med. 2008 Oct-Nov; 16(4):117-21. PMID: 18838745.
      View in: PubMed
    38. Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S. Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res. 2008 Feb; 28(2):89-100. PMID: 18279104.
      View in: PubMed
    39. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med. 2007 Mar 26; 167(6):597-605. PMID: 17389292.
      View in: PubMed
    40. Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Pollard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu R. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis. 2006 Dec 15; 194(12):1672-6. PMID: 17109338.
      View in: PubMed
    41. Martin BK, Wu AW, Gelman R, Mitsuyasu RT. Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration. J Acquir Immune Defic Syndr. 2005 Dec 01; 40(4):428-33. PMID: 16280697.
      View in: PubMed
    42. Kuekrek H, Schlingmann T, Valdez H, Boehm BO, Pollard RB, Mitsuyasu R, Goebel FD, Lederman MM, Lehmann PV, Tary-Lehmann M. Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS. 2005 Nov 18; 19(17):1967-74. PMID: 16260902.
      View in: PubMed
    43. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004 May 15; 38(10):1454-63. PMID: 15156485.
      View in: PubMed
    44. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Boyd MP, MacPherson JL, Fanning GC, Todd AV, Ely JA, Zack JA, Symonds GP. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther. 2004 Mar; 15(3):251-62. PMID: 15018734.
      View in: PubMed
    45. Ngok FK, Mitsuyasu RT, Macpherson JL, Boyd MP, Symonds GP, Amado RG. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004; 252:581-98. PMID: 15017082.
      View in: PubMed
    46. de Boer AW, Markowitz N, Lane HC, Saravolatz LD, Koletar SL, Donabedian H, Yoshizawa C, Duliege AM, Fyfe G, Mitsuyasu RT. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells. Clin Immunol. 2003 Mar; 106(3):188-96. PMID: 12706405.
      View in: PubMed
    47. Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Spritzler J, Kalams SA, Pollard RB, Fahey J, Fox L, Namkung A, Estep S, Moss R, Sahner D, Lederman MM. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis. 2003 Jan 15; 187(2):320-5. PMID: 12552459.
      View in: PubMed
    48. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS. 2003 Jan 03; 17(1):53-63. PMID: 12478069.
      View in: PubMed
    49. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002 Jul 10; 288(2):169-80. PMID: 12095381.
      View in: PubMed
    50. Sha BE, Valdez H, Gelman RS, Landay AL, Agosti J, Mitsuyasu R, Pollard RB, Mildvan D, Namkung A, Ogata-Arakaki DM, Fox L, Estep S, Erice A, Kilgo P, Walker RE, Bancroft L, Lederman MM. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses. 2002 Jun 10; 18(9):661-5. PMID: 12079562.
      View in: PubMed
    51. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. 2002 Jun; 5(6):788-97. PMID: 12027564.
      View in: PubMed
    52. Mitsuyasu R. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients. J Infect Dis. 2002 May 15; 185 Suppl 2:S115-22. PMID: 12001032.
      View in: PubMed
    53. Leibowitz MR, Mitsuyasu RT. Immune Reconstitution Strategies in HIV. Curr Infect Dis Rep. 2001 Jun; 3(3):302-308. PMID: 11384562.
      View in: PubMed
    54. Mitsuyasu RT. The potential role of interleukin-2 in HIV. AIDS. 2001 Feb; 15 Suppl 2:S22-7. PMID: 11424973.
      View in: PubMed
    55. Mitsuyasu R. Prevention of bacterial infections in patients with advanced HIV infection. AIDS. 1999; 13 Suppl 2:S19-23. PMID: 10596677.
      View in: PubMed